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Reproduced from Hoffman, S. J. and Outterson, K. (2015), What Will It Take to
Address the Global Threat of Antibiotic Resistance? Journal of Law, Medicine & EthicsOn 21st September 2016, for only the 4th time in history, a
health topic will take centre stage at a United Nations General
Assembly (UNGA) high-level meeting where heads of state are
present. A day-long session has been convened to discuss the
global threat from the lack of access to antimicrobials and from
increasing antimicrobial resistance (AMR). The main focus will be
on antibiotic resistance. The involvement of the UN underlines the
signiﬁcance of this threat to public health, food security, global
economic growth, and progress towards the 2030 Sustainable
Development Goals.1
Like climate change, AMR depends on effectively managing
global public goods and common resources, in this case
antimicrobials, whose use drives resistance, and thereby deprives
others of their beneﬁts. Such management requires interdepen-
dent action in three areas: conservation, access and innovation
(ﬁgure 1).
Akin to the reduction in use of fossil fuels to curb pollution
levels that impact on climate, conserving antimicrobials to limit
development of resistant microbes, thereby ensuring the continu-
ation of their efﬁcacy for all in need, is a critical strategic response.
This must occur in parallel with existing efforts to promote greater,
appropriate access to antimicrobials for the millions of people who
currently, unfairly face disease without them. Simultaneously, re-
igniting a dormant antimicrobial research and development (R&D)
pipeline to produce new classes of antimicrobials is equally
important to renew this crucial man-made resource. The formation
of DNDi/WHO’s drug accelerator program, the Global Antibiotic
Research and Development (GARD) Partnership2, as well as new
funding streams like Combating Antibiotic-Resistant Bacteria
Biopharmaceutical Accelerator (CARB-X)3 and the nascent Global
Antimicrobial Resistance Innovation Fund (GAMRIF)4 are welcome
and timely initiatives. However, if we are to ultimately reverse or
indeed decelerate our new reality of the post-antibiotic era, then
antibiotic conservation is going to need to take centre stage in an
overarching strategy for AMR control, while we wait for new
products to be developed, and even once we have them. This will
be an ever-lasting battle, which will require strong conservation
policies to be put in place permanently.
Much of the global overuse of antimicrobials occurs in low- and
middle-income countries (LMICs), topped by the BRICS nations
(Brazil, Russia, India, China and South Africa) driving consumption
in both animal and human sectors.5 In general, an increased
demand for animal protein accompanies the transition from low to
higher incomes6 and is currently met by more intensive farminghttp://dx.doi.org/10.1016/j.ijid.2016.09.016
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International S
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).practices. Historically, these practices rely on sub-therapeutic
doses of antibiotics for animal growth promotion (AGP), a practice
banned in the European Union since 2006, as well as wide scale
treatment of healthy animals to prevent them getting sick
(metaphylaxis), and hence avoiding reduced productivity. Veteri-
narian prescribing controls a comparatively small percentage of
total use in animals.
Although not conﬁned to LMICs, the drivers of antimicrobial
overuse and misuse in human health are multifactorial and
magniﬁed in these settings by the still massive burden of infectious
diseases, high poverty levels leading to lack of access to clean
water, sanitation and hygiene, unregulated access to antimicro-
bials over-the-counter and from street-sellers without prescrip-
tion, cultural perceptions of antimicrobials (antibiotics in
particular) as conﬁrmation of illness and vindication of being
unwell, and lack of education of healthcare professionals and the
public in terms of the adverse effects that inappropriate
antimicrobial use exacts on the public health. In addition,
aggressive marketing and a limited regulatory and enforcement
capacity of pharmaceutical company practice can drive overuse in
some settings.43(S3): 6–11. doi:10.1111/jlme.12267.
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10 million AMR-related deaths per year will occur by 2050.7 The
catch-22 is that these are the countries that generally need
improved access to antimicrobials and are the least able to ﬁnance
conservation efforts due to resource limitations and weaker health
systems.
The ﬁnal O’Neill Report on Antimicrobial Resistance highlights
10 interventions that are needed to address the global antimicro-
bial resistance crisis.8 Its recommendation of a global innovation
fund to drive R&D for new antimicrobials, vaccines and diagnostics
has been a focus of attention in the run up to UNGA, and is an
important initiative. However, for many LMICs, it is clear that
government budgets will only go so far in supporting each stage of
the process towards antimicrobial conservation, and serious
consideration must be given to how low income, and lower-
middle income countries are going to translate their national
action plans into practice without international ﬁnancial and
technical assistance? Furthermore, how will countries that receive
such aid be held accountable for delivering on commitments
made? How will countries conserve new antimicrobials with the
current challenges they face that have contributed to the AMR
crisis?
We recommend the formation of a Global Antimicrobial
Conservation Fund to complement the tranche of innovation
funds that have recently been announced. Rather than this being a
permanent ﬂow of funds, which is unsustainable, a conservation
fund would provide transitional ﬁnancial and technical support to
build capacities and programs within the poorest countries, which
would then be taken over domestically as possible. Such a fund
would not diminish the responsibility of national governments in
the development of their national AMR plans nor for delivering
meaningful outputs. Rather, it would confer support for accelerat-
ed action, to conserve a rapidly dwindling resource and could be
linked to a formal resource conservation agreement. For those
wealthier countries already spending considerably on AMR,
ﬁnancially contributing to such a global conservation fund protects
their domestic investments and is one of the most cost-effective
ways of mitigating risk posed by the transnational migration of
resistant microbes.
Surveillance of antimicrobial resistance and consumption
forms a critical pillar of all AMR national action plans. Countries
have been encouraged to join the Global Antimicrobial Resistance
Surveillance System (GLASS)9, yet few LMICs in Africa, Asia and
South America have the laboratory infrastructure and reporting
mechanisms in place to provide meaningful input or to qualify for
inclusion. Transitional ﬁnancial and technical support to individual
countries to stimulate growth and build human resource capacity
in surveillance is crucial, but forming or strengthening regional
collaborative networks also needs consideration by funding
mechanisms such as the Fleming Fund.10 A ‘hub-and-spoke’ model
where a country or countries with greater laboratory and
surveillance infrastructure in place supports regional neighbors
is an attractive one. However, additional funding mechanisms to
the £250 million Fleming Fund will be needed to make signiﬁcant
inroads into the lack of surveillance infrastructure across the vast
majority of developing countries. LMICs will equally need to be
supported in the area of documenting consumption and the types
of antimicrobials in their markets under the whole surveillance
umbrella.
Three other important conservation strategies that require
international funding are highlighted in the O’Neill report; public
awareness campaigns, building human resources, and infection
prevention interventions. A sustained, global, public awareness
campaign on antimicrobial resistance and conservation is esti-
mated to require USD $40-100 million per annum. The Indian red
line campaign, which identiﬁes antibiotics or products containingthem, is the ﬁrst attempt to make antimicrobials easily identiﬁable
to the public, and could be rolled out internationally possibly
combined with regulating antimicrobials as a separate class of
medicines.11 Yet a more diverse approach may be needed, which
takes into account how different societies in LMICs deliver health
information. This may be as diverse as oral story telling around the
village ﬁreplace and other traditional community-based teaching
methods, all the way up to the use of comparatively high
technology social media campaigns.
This issue also speaks to how we are to ﬁnance the building of
human resources to undertake communication and all the other
facets of a stewardship response in resource poor settings. A lack of
remuneration for doctors working in the ﬁeld of Infection
compared to most other clinical specialties has been identiﬁed.8
While it is important to stimulate the global growth of clinical and
laboratory specialists in Infection, it is far more important to
broaden the discussion to consider which cadres of health care
professionals (HCPs) are best placed to steward antimicrobials
towards their optimal use and how we are going to ﬁnance growth
across many human resources needs. There will not be a ‘one size
ﬁts all’ model for all countries; rather, ﬂexibility in the model or
framework will be required. Indeed, studies from LMICs of
stewardship programs run by doctors12, pharmacists13, nurses14,
and community health workers15 have already highlighted the
diversity of programs that can lead to signiﬁcant reduction in
antimicrobial consumption and the optimization of their use in
public and private sectors. The barrier is frequently not just the
number of HCPs available, but that time is not apportioned to their
working day to enact stewardship. There is often so little leeway in
the system, that asking HCPs to take on extra tasks or reduce some
of their existing workload to accommodate stewardship activities
is often impractical. Extra ﬁnances and a harmonization across
donor-driven vertical health programmes that often compete for
the time and attention of a limited number of health staff will be
needed on a transitional basis for LMICs to address this shortfall.
The third and perhaps most fundamental intervention for
antimicrobial conservation that will require additional funding in
LMICs is delivery of basic infection prevention measures for
communicable diseases. LMICs continue to face the challenge of
unsafe water and poor sanitation, which drives diarrhoeal diseases.
Basic necessities like running water and sanitizing agents are often
lacking in health facilities outside of the major cities. Others do not
have the ﬁnances to deliver essential vaccination programs to
protect children against pneumonia and other vaccine preventable
infections. In food production, infection prevention i.e., increasing
biosafety and biosecurity are core components to change that
would be necessary to assure food security if AGPs are to be rapidly
phased out and metaphylaxis for healthy animals either banned or
limited.16,17 Without external ﬁnancial aid, many LMICs are
unlikely to be able to put in place the public health interventions
that have formed the bedrock of antimicrobial conservation in
high-income countries.
Calls for the formation of a high-level coordinating mechanism
to oversee the next phase of the global response to AMR are being
made in the run up to the UNGA high level meeting.18 One function
of such a body could be to coordinate how funds from governments
and foundations should be spent. A rapid scaling up of funding for
low- and lower-middle income developing countries to support
antimicrobial conservation in the form of a Global Antimicrobial
Conservation Fund should be a critical component of the
deliberations to come.
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